rs1060499542
Variant summary
Our verdict is Likely pathogenic. Variant got 7 ACMG points: 7P and 0B. PM2PM5PP3_ModeratePP5
The NM_002609.4(PDGFRB):c.1696T>C(p.Trp566Arg) variant causes a missense change involving the alteration of a conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. 12/21 in silico tools predict a damaging outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. W566?) has been classified as Pathogenic.
Frequency
Consequence
NM_002609.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Likely_pathogenic. Variant got 7 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
PDGFRB | NM_002609.4 | c.1696T>C | p.Trp566Arg | missense_variant | Exon 12 of 23 | ENST00000261799.9 | NP_002600.1 | |
PDGFRB | NM_001355016.2 | c.1504T>C | p.Trp502Arg | missense_variant | Exon 11 of 22 | NP_001341945.1 | ||
PDGFRB | NM_001355017.2 | c.1213T>C | p.Trp405Arg | missense_variant | Exon 12 of 23 | NP_001341946.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
PDGFRB | ENST00000261799.9 | c.1696T>C | p.Trp566Arg | missense_variant | Exon 12 of 23 | 1 | NM_002609.4 | ENSP00000261799.4 | ||
PDGFRB | ENST00000520579.5 | n.*1010T>C | non_coding_transcript_exon_variant | Exon 12 of 23 | 1 | ENSP00000430026.1 | ||||
PDGFRB | ENST00000520579.5 | n.*1010T>C | 3_prime_UTR_variant | Exon 12 of 23 | 1 | ENSP00000430026.1 | ||||
PDGFRB | ENST00000520229.1 | n.-36T>C | upstream_gene_variant | 3 |
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD4 exome Cov.: 31
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
Skeletal overgrowth-craniofacial dysmorphism-hyperelastic skin-white matter lesions syndrome Pathogenic:2
Based on the classification scheme VCGS_Germline_v1.1.1, this variant is classified as Pathogenic. Following criteria are met: 0103 - Both loss- and gain-of-function are known mechanisms of disease for this gene. Loss-of-function: idiopathic basal ganglia calcification (IBGC) syndrome Type 4. Gain-of-Function: infantile myofibromatosis, Penttinen syndrome, and Kosaki overgrowth syndrome (PMID: 31004414) (N) 0107 - This gene is known to be associated with autosomal dominant disease. (N) 0200 - Variant is predicted to result in a missense amino acid change from tryptophan to arginine (exon 12). (N) 0251 - Variant is heterozygous. (N) 0301 - Variant is absent from gnomAD. (P) 0501 - Missense variant consistently predicted to be damaging by multiple in-silico tools or highly conserved with a major amino acid change. (P) 0600 - Variant is located in an annotated domain or motif (juxtamembrane domain (PMID: 30941910). (N) 0705 - No comparable variants have previous evidence for pathogenicity. (N) 0801 - Strong previous evidence of pathogenicity in unrelated individuals (ClinVar, Minatogawa, M. et al. (2017), PMID: 28639748, 30941910). (P) 1001 - Strong functional evidence supporting abnormal protein function. Functional studies on patient cells indicated that the variant constitutively activates the PI3K-AKT pathway (PMID: 30941910). (P) Legend: (P) - Pathogenic, (N) - Neutral, (B) - Benign -
- -
Dandy-Walker syndrome Pathogenic:1
- -
Hydrocephalus;C4551572:Myofibromatosis, infantile, 1 Pathogenic:1
- -
not provided Pathogenic:1
The W566R variant in the PDGFRB gene has not been reported previously as a germline pathogenic variant nor as a benign variant, to our knowledge. However, functional studies in tumor cells showed W566R was constitutively activated in contrast to the unstimulated wild-type receptor and was constitutively phosphorylated on tyrosines in NIH3T3 fibroblasts (Arts et al., 2017). The W566R variant is not observed in large population cohorts (Lek et al., 2016; 1000 Genomes Consortium et al., 2015; Exome Variant Server). The W566R variant is a non-conservative amino acid substitution, which occurs at a position that is conserved across species. In silico analysis predicts this variant is probably damaging to the protein structure/function. We interpret W566R as a pathogenic variant -
Infantile myofibromatosis;C1866182:Acroosteolysis-keloid-like lesions-premature aging syndrome;C3554321:Basal ganglia calcification, idiopathic, 4;C4225270:Skeletal overgrowth-craniofacial dysmorphism-hyperelastic skin-white matter lesions syndrome Pathogenic:1
This sequence change replaces tryptophan, which is neutral and slightly polar, with arginine, which is basic and polar, at codon 566 of the PDGFRB protein (p.Trp566Arg). This variant is not present in population databases (gnomAD no frequency). This missense change has been observed in individual(s) with Kosaki overgrowth syndrome (PMID: 28639748, 30941910). In at least one individual the variant was observed to be de novo. ClinVar contains an entry for this variant (Variation ID: 375682). Invitae Evidence Modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) has been performed for this missense variant. However, the output from this modeling did not meet the statistical confidence thresholds required to predict the impact of this variant on PDGFRB protein function. For these reasons, this variant has been classified as Pathogenic. -
Infantile myofibromatosis Pathogenic:1
The p.W566R mutation was found in one patient with myofibromatosis. It activates PDGFRB signaling in cell culture (gain of function). We sequenced PDGFRB in myofibromatosis cases using the Ion Torrent technology. All variants were confirmed by an alternative method (allele specific PCR or Sanger sequencing). Mutants were functionally characterized in experiments based on cell transfection. In our patient, the p.W566R mutation was associated with a second mutation, c.1998C>A (p.N666K), which also activates the receptor. The two mutations were found in cis (on the same PDGFRB allele). -
Inborn genetic diseases Uncertain:1
- -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at